Construction of the nucleic vaccine pVVP3L-18HN and its antitumor effect on human laryngeal carcinoma.
- Author:
Guo-fang GUAN
1
;
Ning-yi JIN
;
Zhi-qiang MI
;
Xiao LI
;
Hai LIAN
;
Chun-shun JIN
;
Li-li SUN
;
Lian-ji WEN
Author Information
- Publication Type:Journal Article
- MeSH: Cancer Vaccines; biosynthesis; Gene Expression; Genetic Vectors; HN Protein; genetics; Hep G2 Cells; Humans; Interleukin-18; genetics; Laryngeal Neoplasms; immunology; prevention & control; Newcastle disease virus; immunology; Plasmids; Transfection; Vaccines, DNA; biosynthesis
- From: Chinese Journal of Otorhinolaryngology Head and Neck Surgery 2005;40(8):566-570
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVENucleic vaccine of pVVP3IL-18HN expressing apoptin gene, Newcastle disease virus HN gene and IL-18 gene were constructed to observe the combinative antitumor effect of the above three genes.
METHODSEukaryotic expression plasmid pVVP3IL-18HN was constructed by inserting apoptin gene and fragment comprising fused IL-18HN gene and IRES promoter into the downstream of CMV promoter of vector pVAX1. The expression of inserted gene was identified by RT-PCR, indirect immunofluorescence and Western-blot. The recombinant plasmid was introduced into Hep-2 cells by liposome, then suppression rate of Hep-2 of different time and different quantity was calculated according to MTT results.
RESULTThe recombinant plasmid of pVVP3IL-18HN suppressed Hep-2 successfully and its suppression rate was up to 61.9% with 20 microg/ml, incubation of 72 hours.
CONCLUSIONThe nucleic vaccine constructed pVVP3IL-18HN had antitumor effect on Hep-2. It may can be used to the therapy and research of laryngeal carcinoma.
